Higher CD4/CD8 ratio of pleural effusion predicts better survival for lung cancer patients receiving immune checkpoint inhibitors

Pleural effusion is a rare immune-related adverse event for lung cancer patients receiving immune checkpoint inhibitors (ICIs). We enrolled 281 lung cancer patients treated with ICIs and 17 were analyzed. We categorized the formation of pleural effusion into 3 patterns: type 1, rapid and massive; ty...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2021-04, Vol.11 (1), p.9381-9381, Article 9381
Main Authors: Lee, Po-Hsin, Yang, Tsung-Ying, Chen, Kun-Chieh, Huang, Yen-Hsiang, Tseng, Jeng-Sen, Hsu, Kuo-Hsuan, Wu, Yu-Chen, Liu, Ko-Jiunn, Chang, Gee-Chen
Format: Article
Language:English
Subjects:
631/67/1059/2325
631/67/1612/1350
631/67/580
CD4 antigen
CD8 antigen
Humanities and Social Sciences
Immune checkpoint inhibitors
Inhibitors
Lung cancer
multidisciplinary
Pleural effusion
Science
Science (multidisciplinary)
Survival
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pleural effusion is a rare immune-related adverse event for lung cancer patients receiving immune checkpoint inhibitors (ICIs). We enrolled 281 lung cancer patients treated with ICIs and 17 were analyzed. We categorized the formation of pleural effusion into 3 patterns: type 1, rapid and massive; type 2, slow and indolent; and type 3, with disease progression. CD4/CD8 ratio of 1.93 was selected as the cutoff threshold to predict survival. Most patients of types 1 and 2 effusions possessed pleural effusion with CD4/CD8 ratios ≥ 1.93. The median OS time in type 1, 2, and 3 patients were not reached, 24.8, and 2.6 months, respectively. The median PFS time in type 1, 2, and 3 patients were 35.5, 30.2, and 1.4 months, respectively. The median OS for the group with pleural effusion CD4/CD8 ≥ 1.93 and 
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-021-89043-4